QSI Earnings Prediction
The chart below shows how QSI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, QSI sees a +20.83% change in stock price 10 days leading up to the earnings, and a +6.17% change 10 days following the report. On the earnings day itself, the stock moves by -3.36%. This data can give you a slight idea of what to expect for the next quarter's release.
QSI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.19M
198.00%
51.46%
Gross Margin
51.17%
14.99%
9.74%
Operating Margin
-2362.00%
-65.53%
-33.82%
Net Margin
-2778.61%
-49.59%
-13.61%
EPS
-0.23
-43.75%
27.78%
No Data Available
QSI Earnings Analysis
Quantum-Si Inc Corporation (QSI.O) Earnings Conference Call
Positive
Platinum Instrument Launch: 2024 marked a significant year for Quantum-Si with the successful commercial launch of the Platinum instrument, leading to consistent quarter-over-quarter revenue growth.
Revenue Surge in Q4: The company achieved a total revenue of $1.2 million in Q4 2024, representing a 52% increase over Q3 2024 and a 183% increase year-over-year.
Customer Base Diversification: Quantum-Si diversified its customer base significantly, expanding from primarily academic researchers to include biotech, pharma, government, and contract research organizations.
Milestone in Commercialization: The company successfully sold its fiftieth Platinum instrument in Q4 2024, marking a key milestone in its commercialization efforts.
Global Distribution Expansion: Quantum-Si established an international distribution channel with eighteen partners, enhancing its global market reach and access to new regions.
Product Launch and Expansion: The company launched two new sequencing kits and a new library prep kit in 2024, expanding proteome coverage and improving sample success rates.
Proteus Platform Launch: The Proteus platform is set to launch in the second half of 2026, promising to significantly enhance proteomics analysis capabilities.
Next-Generation Protein Sequencing: Quantum-Si's scientific affairs team submitted four manuscripts for peer review, showcasing the value of next-generation protein sequencing and its applications.
Capital Raising and Cash Runway: The company raised capital through its at-the-market facility, providing an extended cash runway into the second half of 2027, supporting its commercial strategy and innovation roadmap.
Negative
Earnings Miss Report: Quantum-Si incorporated misses on earnings expectations with reported EPS of $-0.23, below the expected $-0.18.
Operating Expenses Increase: Total operating expenses for Q4 2024 were $31.3 million, an increase from $28.1 million in Q4 2023, indicating rising costs.
SG&A Expense Increase: SG&A expenses increased by 13% year-over-year, reflecting higher costs associated with ramping up commercialization efforts.
Revenue vs. Investor Expectations: Despite a 52% increase in revenue from Q3 2024, total revenue for Q4 2024 was only $1.2 million, which may not meet investor expectations for growth.
Gross Margin Analysis: The gross margin for Q4 2024 was 51%, which may be considered low for a company in the growth phase, and is expected to remain variable due to ongoing commercialization efforts.
NIH Funding Uncertainty: There is uncertainty surrounding the NIH funding environment for 2025, which could impact the academic research market and delay capital spending plans for some customers.
Q1 Revenue Projection: The company anticipates revenue for Q1 2025 to be at least $900,000, which, while representing 100% growth year-over-year, reflects a typical drop-off in revenue from Q4 to Q1.
QSI FAQs
How does QSI typically perform around its earnings report dates?
Is Quantum-Si Inc (QSI) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
QSI Earning Call Sentiment
Quantum-Si incorporated (NASDAQ:QSI) Q4 2024 Earnings Call Transcript
QSI.O
19.3%Positive
The earnings call reveals mixed signals. While revenue and gross profit have shown significant growth, expenses are rising, and competitive pressures exist. The Q&A indicates a cautious approach with longer sales cycles and no immediate impact from new product launches. Positive feedback from communities and a strong cash position are offset by unclear management responses and potential market pressures. Overall, the sentiment is neutral, with some positive elements balanced by uncertainties and challenges.
